Search clinical trials for: EDP-788

Total 3076 results

Enanta Pharmaceuticals, Inc

Completed

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

Safety in Normal Volunteers

United States
Enanta Pharmaceuticals, Inc

Terminated

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

Healthy

United States
University of Edinburgh
Umeå University

Completed

The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin

Coronary Disease

Sweden
Southern Illinois University Edwardsville

Terminated

Effects of Resistance Training on Substrate Metabolism During the Menstrual Cycle

Menstrual Cycle | Substrate Metabolism

United States
Southern Illinois University Edwardsville

Terminated

Effects of Resistance Training in Body Composition and Body Image Perception of Women Throughout the Menstrual Cycle

Body Image Disturbance

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Renal Impairment | Healthy Volunteers

United States
Azienda Ospedaliera Città della Salute e della...

Completed

Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions (PROMENADE)

Patient Discharge

Italy
Northwell Health
National Institute on Aging (NIA)

Active, not recruiting

Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program (ED-DDP)

Delirium

United States
Amsterdam UMC, location VUmc

Active, not recruiting

Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy (RaRe)

Prostate Cancer Metastatic to Bone

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Medical University of Vienna

Completed

Endothelin-Receptor Blockade in Coronary Heart Disease

Vascular Resistance | Coronary Vessels | Endothelins

Austria
Enanta Pharmaceuticals, Inc

Terminated

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Non-Alcoholic Steatohepatitis

United States, Canada, Puerto Rico, United Kingdom, Argentina, Germany
University Hospital, Rouen

Completed

Role of Endothelin-1 in Flow-mediated Dilatation (Endothelin)

Healthy Conditions

France
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Completed

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

RSV Infection

United Kingdom
Enanta Pharmaceuticals, Inc
ICON Clinical Research; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

United States, United Kingdom, New Zealand, Canada, France, Puerto Rico
Enanta Pharmaceuticals, Inc

Completed

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

MRSA, SSTI

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NASH - Nonalcoholic Steatohepatitis

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NASH

United States, Czechia, Slovakia
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Respiratory Syncytial Virus (RSV)

United States
He Xia

Unknown

Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma (NPC-RCT-WCRT)

Nasopharyngeal Carcinoma
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
Sun Yat-sen University
The First Affiliated Hospital of Guangdong Pharmaceutical University; Guangzhou... and other collaborators

Completed

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP 938 Regimens in Children With RSV (RSVPEDs)

Respiratory Syncytial Virus (RSV)

United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (SPRINT)

COVID-19

United States
Enanta Pharmaceuticals, Inc

Recruiting

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. (RSVHR)

RSV Infection

United States, Poland, Spain, Taiwan, Bulgaria, Argentina, Puerto Rico, Czechia, Brazil, Israel, Malaysia, Netherlands, Slovakia, South Africa
Enanta Pharmaceuticals, Inc
PPD

Completed

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects (RSVP)

Respiratory Syncytial Virus

United States, New Zealand, Bulgaria, Argentina, Poland, South Africa, Ukraine
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-323 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-235 in Healthy Subjects

SARS CoV 2 Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
AbbVie (prior sponsor, Abbott)
Prostate Cancer Clinical Trials Consortium

Completed

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Prostate Cancer
Ono Pharmaceutical Co. Ltd

Completed

Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 (ONO-5788-02)

Acromegaly

Netherlands
Zhujiang Hospital

Completed

The Effect of EDP on Diaphragmatic Function and Neural Respiratory Drive in Patient With AECOPD

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

China
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
Northwell Health
National Institute on Aging (NIA)

Active, not recruiting

Implementation Outcome Assessments of the Emergency Department Delirium Screening and Detection Program (ED-DDP)

Delirium

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
NeurAxon Inc.

Completed

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

Migraine Without Aura

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Healthy

United States
AbbVie

No longer available

Expanded Access to Veliparib

High Grade Serous Ovarian Cancer | Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound | Triple Negative Breast Cancer (TNBC) | Patients Requiring Veliparib Suspension Formulation
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm

United States

Search clinical trials for: EDP-788

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations